Fredun Pharmaceuticals Limited

Company Profile

Fredun Pharmaceuticals Limited had its IPO on under the ticker symbol 539730.

The company operates in the Other sector and Other industry. Fredun Pharmaceuticals Limited has a staff strength of 0 employees.

Stock update

Shares of Fredun Pharmaceuticals Limited opened at ₹899.95 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹860 - ₹910, and closed at ₹881.15.

This is a -2.61% slip from the previous day's closing price.

A total volume of 4,320 shares were traded at the close of the day’s session.

In the last one week, shares of Fredun Pharmaceuticals Limited have slipped by -10.09%.

Fredun Pharmaceuticals Limited's Key Ratios

Fredun Pharmaceuticals Limited has a market cap of ₹898.47 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months Fredun Pharmaceuticals Limited’s revenue was ₹0 with a gross profit of ₹0 and an EBITDA of ₹0. The EBITDA ratio measures Fredun Pharmaceuticals Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Fredun Pharmaceuticals Limited’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.

In Q0.33333333333333, Fredun Pharmaceuticals Limited’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Fredun Pharmaceuticals Limited’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at ₹0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Fredun Pharmaceuticals Limited’s profitability.

Fredun Pharmaceuticals Limited stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

Fredun Pharmaceuticals Limited stock pays annual dividends of ₹ per share, indicating a yield of None and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

₹2.57 billion

Total Liabilities

₹1.06 billion

Operating Cash Flow

₹0

Capital Expenditure

₹0

Dividend Payout Ratio

0%

Fredun Pharmaceuticals Limited ended 2025 with ₹2.57 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹2.57 billion while shareholder equity stood at ₹963.76 million.

Fredun Pharmaceuticals Limited ended 2025 with ₹0 in deferred long-term liabilities, ₹1.06 billion in other current liabilities, 45323000.00 in common stock, ₹918.44 million in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹4.89 million and cash and short-term investments were ₹162.50 million. The company’s total short-term debt was ₹375,962,000 while long-term debt stood at ₹489.29 million.

Fredun Pharmaceuticals Limited’s total current assets stands at ₹2.16 billion while long-term investments were ₹0 and short-term investments were ₹128.15 million. Its net receivables were ₹345.60 million compared to accounts payable of ₹6000.00 and inventory worth ₹1.50 billion.

In 2025, Fredun Pharmaceuticals Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Fredun Pharmaceuticals Limited paid ₹0 in dividends in 2025.

Other key metrics

Current Trading Price

₹881.15

52-Week High

₹1428

52-Week Low

₹740

Analyst Target Price

₹

Fredun Pharmaceuticals Limited stock is currently trading at ₹881.15 per share. It touched a 52-week high of ₹1428 and a 52-week low of ₹1428. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹949.12 and 200-day moving average was ₹956.98 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.